Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Bayer plc, 400 South Oak Way, Reading, RG2 6AD
Progynova TS 50 micrograms/24 hours Transdermal Patch.
| Pharmaceutical Form |
|---|
|
Transdermal patch. Oval transdermal patch with a translucent homogenous matrix on a transparent carrier film. |
Each 12.5 cm² patch contains 3.8 mg estradiol (formed from 3.9 mg estradiol hemihydrate), releasing a nominal 50 micrograms of estradiol per 24 hours.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Estradiol |
Estradiol, is chemically and biologically identical to endogenous human estradiol. It substitutes for the loss of oestrogen production in menopausal women, and alleviates menopausal symptoms. Oestrogens prevent bone loss following menopause or ovariectomy. |
| List of Excipients |
|---|
|
Isooctyl acrylate/acrylamide/vinyl acetate copolymer |
Each patch is sealed in a multilaminate pouch containing a desiccant. The desiccant consists of sodium alumino silicate;
Pack of 4 or 12 patches.
(Not all pack sizes may be marketed).
Bayer plc, 400 South Oak Way, Reading, RG2 6AD
PL 00010/0560
11 July 2010
| Drug | Countries | |
|---|---|---|
| PROGYNOVA | Austria, Australia, Germany, Spain, Finland, France, Israel, Malta, Netherlands, New Zealand, Singapore, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
